Regardless of the fact that this group offers benefited tremendously from particular biological therapies directed at this subtype , many tumours continue to advance and metastasize. ‘Whenever a individual with this breast malignancy subtype stops responding to the original drug and the disease progresses, a second drug is administered. It could be that the response to both of these treatments is usually negligible or there could even become no response at all and the tumour is growing. In the fight against cancer, the mix of treatments is highly common practice. However, the concept described is different: it is not about seeing the outcomes of combining drug A with medication B, but, whenever a fails to work, B is certainly administered, and if this also fails we return to the starting place and initiate treatment with a combined mix of the two .The scientific challenges are finding a vaccine and a cure. We really need both of these in order to see the final end of Helps. Where can visitors find more information? has some great information, including videos, webcasts, summaries of the classes and so forth. About Professor Sharon Lewin Professor Lewin is an infectious diseases doctor and basic scientist. She is Director of the Infectious Illnesses Device at the Alfred Hospital; Professor of Medicine, Division of Medicine, Monash University; co-mind of the Centre for Virology, Burnet Institute, Melbourne, Australia; and an Australian National Health insurance and Medical Analysis Council practitioner fellow.